CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT03316573
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:27.573059+00:00
- Published At
- 2023-11-22T00:00:00+00:00
- Record Updated At
- 2026-02-10
- Results Posted At
- 2023-11-22
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Lymphoma", "Histiocytic Sarcoma", "Follicular Dendritic Cell Sarcoma", "Interdigitating Dendritic Cell Sarcoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-10"- protocolSection.identificationModule.nctId
"NCT03316573"- protocolSection.identificationModule.officialTitle
"A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas"- protocolSection.statusModule.overallStatus
"SUSPENDED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-11-22"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.